drugset / Trial / NCT00138736
Study on Mannan Binding Lectin (MBL) Substitution in MBL-Deficient Children With Chemotherapy-Induced Neutropenia
Phase 2
Completed
12 enrolled
Prothya Biosolutions
Landsteiner Foundation for Blood Transfusion · collab
Non-randomizedSingle-groupOpen-labelPrevention
Summary
The pharmacokinetics, and clinical and biological effects of MBL replacement therapy in MBL-deficient children during chemotherapy-induced neutropenia were studied.
Timeline
- Start
- 2004-04
- Primary completion
- —
- Completion
- 2006-10
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Mannan Binding Lectin | Unknown | 0.2 mg/kg | — |
| Subject | Mannan Binding Lectin | Unknown | 0.3 mg/kg | — |